Infliximab: una alternativa en la eritrodermia psoriásica refractaria

Pedreira, Iván Suárez; Santos‐Juanes, Jorge; Montero, Luis Caminal; Trapiella, Luis

doi:10.1016/s0213-9251(06)72498-4

Search citation statements

Order By: Relevance

Paper Sections

Select...

Mycophenolate Mofetil (Mmf)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…49,52 Infliximab Infliximab, a chimeric monoclonal antibody, is considered to be a first-line biologic for EP due to its rapid onset. 1,44,52,53,[55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70] In one multicenter study that included 24 patients, 52 one-third of the patients achieved PASI 75 at week 4 with infliximab treatment. But longterm efficacy is not so promising, as at the same study that only 48% of patients achieved PASI 75 at week 14, 52 and one case reported no further improvement after the sixth infusion of infliximab; the subject's condition was then controlled by administration of etanercept.…”

Section: Mycophenolate Mofetil (Mmf)mentioning

confidence: 99%

Updates on the Treatment of Erythrodermic Psoriasis

Lo¹,

Tsai

2021

PTT

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP.

show abstract